



# Diabetic Nephropathy Market | Pricing Scenario, Supply Chain Analysis | Forecast – 2023

Diabetic Nephropathy Market Growth is Owing to Growing Prevalence of Diabetes. The Diabetic Nephropathy industry is expected to grow at a CAGR of 5.2% over the forecast period 2017 to 2023. The latest research report is published by Market Research Future (MRFR).

## Global Diabetic Nephropathy Market Overview

The global diabetic nephropathy market is growing pervasively, mainly due to the technological advancements happened in diabetic care. The number of diabetic patients is exploding at an alarming rate. Diabetes if not treated well can to severe and life-threatening conditions such as kidney failure.

Early diagnosis and treatment not only reduce the chances of further damages to the kidney but also help in diabetes management. The spreading awareness about diabetic nephropathy and the demand for treatments to manage this condition is escalating the market on the global level.

Considering the exponential growth, the market perceives currently, Market Research Future (MRFR) in its recently published study report asserts that the global diabetic nephropathy market will witness exponential accruals by 2023, registering 5.2% CAGR throughout the assessment period (2017-2023).

**Get a FREE Sample (Including COVID19 Impact Analysis, Full TOC, Tables and Figures) of Diabetic Nephropathy Market @**

[https://www.marketresearchfuture.com/sample\\_request/5664](https://www.marketresearchfuture.com/sample_request/5664)

Additional factors such as the substantial funding for research in the field of diabetes diagnosis and treatment alongside the rising number of approvals from regulatory bodies are boosting the growth of the market. Moreover, the increasing prevalence of chronic diseases such as obesity, diabetes, and increasing demand for diagnostic tests including urine test, blood test, kidney biopsy, and imaging tests like MRI and CT scan drive the growth of the market.

Conversely, factors such as the lack of awareness among people towards the availability of the treatment for diabetic nephropathy are hampering the growth of the market. Nevertheless, factors such as the increasing healthcare expenditure, and funding program from the government will support the growth of the market.

## Global Diabetic Nephropathy Market – Segments

For ease of understanding, the market is segmented into five key dynamics: -

**By Diagnosis:** Urine Test, Blood Test, Imaging Tests, Renal Function Testing, and Kidney Biopsy among others.

**By Treatment:** Medications, Kidney Dialysis, and Transplant among others.

**By Indication:** Diabetes 1, Diabetes 2

**By End-user:** Hospital & Clinic, Diagnostic Center, Research Institutes, and others.

**By Regions:** Europe, Asia Pacific, North America, and the Rest-of-the-World.

### **Global Diabetic Nephropathy Market – Regional Analysis**

North America, heading with the presence of a vast patient population accounts for the leading position in the global diabetic nephropathy market. Additional factors that are supporting the market to substantiate include the presence of well-developed healthcare infrastructure and the leading players. Also, the increasing emphasis on diagnosis and continuous monitoring of diabetes and high blood pressure and extensive use of diagnostic tests propel the growth of the regional market.

Furthermore, the high prevalence of various kidney diseases and support from the companies, private organization, and government associations to improve diabetes care in the region drive the growth of the diabetic nephropathy market in North America.

The diabetic nephropathy market in the European region holds the second-largest position, globally. Certainly, the resurging economy is playing an important role in supporting the market growth in the region, availing the best possible healthcare and increasing the per capita healthcare expenditures.

Besides, factors such as the government support that encourage the players to develop high-quality technologies for diabetes care and favorable reimbursement policies are fostering the growth in the regional market.

The Asia Pacific diabetic nephropathy market is rapidly emerging as a profitable market, globally. The prevalence of chronic diseases like cardiovascular diseases, diabetes, kidney disease, and obesity, especially among the geriatric population is a key driving force behind the growth of the regional market. Moreover, factors such as the proliferating healthcare sector and spreading awareness among individuals towards diabetic care and advantages and the availability of diabetic nephropathy drive the growth of the market in the region.

### **Global Diabetic Nephropathy Market – Competitive Analysis**

Highly competitive, the diabetic nephropathy market appears to be widely expanded and fragmented due to the presence of several small and large-scale players. These players incorporate various strategic initiatives like the partnership, acquisition, collaboration, expansion, and product launch to gain an edge over their competitors.

#### **Major Players:**

Key players leading the global diabetic nephropathy market include Bayer AG (Germany), Merck & Co., Inc. (U.S.), Abbott (U.S.), Novartis AG (Switzerland), Sanofi (France), Reata Pharmaceuticals, Inc. (U.S.), AbbVie Inc. (U.S.), Pfizer Inc. (U.S.), Eli Lilly and Company

(U.S.), Siemens AG (Germany), General Electric Company (U.S.), and Mitsubishi Tanabe Pharma Corporation (Japan) among others.

**Obtain Premium Research Report Details, Considering the impact of COVID-19 @ <https://www.marketresearchfuture.com/reports/diabetic-nephropathy-market-5664>**

**Industry/ Innovation/ Related News:**

**March 12, 2019** — Crown Bioscience, Inc. (the US), a global drug discovery and development services company that also provides translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research announced the signing of a licensing agreement with the Research Models and Services business of Charles River Laboratories International, Inc.

Proprietary to CrownBio, the ZDSD is a novel model of diabetic nephropathy and this agreement is expected to help CrownBio with a higher global model availability for drug discovery in obesity, diabetes, and metabolic syndrome. The deal, designed to increase the access to CrownBio's ZDSD rat will provide Charles River with an exclusive license to breed and distribute the ZDSD model.

**About Market Research Future:**

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

**Contact:**

**Market Research Future**

**+1 646 845 9312**

**Email: [sales@marketresearchfuture.com](mailto:sales@marketresearchfuture.com)**

**NOTE: Our team of researchers are studying Covid-19 and its impact on various industry verticals and wherever required we will be considering covid-19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.**

